GSK wins jury verdict in Illinois ranitidine cancer case

GSK

GSK plc has welcomed today’s jury verdict in the Joiner case in Illinois state court finding in GSK’s favour.

·   Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer

·   Verdict is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer

·   GSK will continue to vigorously defend itself against all other claims

This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims.

Prior to this verdict, the court rejected the Plaintiff’s ability to request punitive damages.

Share on:

Latest Company News

Japan expands approval of GSK’s Arexvy to at-risk adults aged 18–49

GSK says Japan has expanded Arexvy eligibility to adults aged 18–49 at increased risk of RSV disease, including immunocompromised patients.

GSK partners with SBP Group to support bepirovirsen launch in China

GSK has entered an exclusive collaboration with SBP Group’s CTTQ unit to accelerate the launch of bepirovirsen, a potential first-in-class chronic hepatitis B treatment currently under priority review in China.

GSK wins China approval for Blenrep in previously treated multiple myeloma

The approval covers Blenrep plus bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma and is supported by phase III DREAMM-7 data showing progression-free and overall survival benefits.

GSK adds pulmonary hypertension candidate HS235 through 35Pharma acquisition

GSK has closed its acquisition of 35Pharma, gaining HS235, a potential treatment for pulmonary hypertension that targets the activin receptor signalling pathway and is expected to enter proof-of-concept trials soon.

GSK expands Exdensur approval in China to CRSwNP

The NMPA has approved Exdensur for adults with chronic rhinosinusitis with nasal polyps, based on phase III data showing improved nasal polyp and obstruction scores, with tolerability similar to placebo.

GSK wins China approval for Exdensur in severe asthma

GSK said China’s National Medical Products Administration approved Exdensur (depemokimab) for severe eosinophilic asthma in adults and adolescents aged 12 and older, supported by phase III data showing sustained exacerbation reduction versus placebo.

    Search